{"url_path":"/sec/dmaa/8-k/2026-07-20/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-079678-index.html","accession_number":"0001213900-26-079678","cik":"0002028614","ticker":"DMAA","issuer_name":"Drugs Made In America Acquisition Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-079678-index.html","primary_entity_key":"0002028614","primary_entity_name":"Drugs Made In America Acquisition Corp."},"word_count":357,"has_tables":true,"body_markdown":"false\n0002028614\n\n0002028614\n\n2026-07-14\n2026-07-14\n\n0002028614\n\nDMAA:UnitsEachConsistingOfOneOrdinaryShareParValue0.0001PerShareAndOneRightToReceiveOneeighth18OfOrdinaryShareMember\n\n2026-07-14\n2026-07-14\n\n0002028614\n\nDMAA:OrdinarySharesMember\n\n2026-07-14\n2026-07-14\n\n0002028614\n\nus-gaap:RightsMember\n\n2026-07-14\n2026-07-14\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n** **\n\n**CURRENT REPORT**\n\nPursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934\n\n** **\n\n**Date of Report (Date of earliest event reported):\nJuly 14, 2026**\n\n** **\n\n**DRUGS MADE IN AMERICA ACQUISITION CORP.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\nCayman Islands\n \n001-42467\n \n99-2394788\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission File Number)\n \n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n420 Lexington Avenue, Suite 1402\n\nNew York, NY 10170\n\n(Address of principal executive offices) (Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: (646) 726-7074\n\n \n\nNot Applicable\n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☒Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n** **\n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\n** **\n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nUnits, each consisting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one-eighth (1/8) of an Ordinary Share\n \nDMAAU\n \nThe Nasdaq Stock Market LLC\n\nOrdinary Shares\n \nDMAA\n \nThe Nasdaq Stock Market LLC\n\nRights\n \nDMAAR\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐"}